Biomed Central Ltd

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Budhu
    Budhu
  3. Hirschhorn Cymerman
    Hirschhorn Cymerman
  4. Iasonos
    Iasonos
  5. Liu
    Liu
  6. Mangarin
    Mangarin
  7. Panageas
    Panageas
  8. Zhou
    Zhou
  9. Adamow
    Adamow
  10. Ariyan
    Ariyan

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Melanoma and Immunotherapeutics Service (6)
  4. GSK Faculty (5)
  5. Biostatistics Service (4)
  6. Epidemiology and Biostatistics (4)
  7. GDMT, Medicine (4)
  8. Gynecologic Medicine Service (4)
  9. Gynecology Disease Management Team (4)
  10. Hematologic Malignancies, Division of (4)
Search Within
  1. "Travis Hollmann"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
  3. Guidelines (1)
  4. Review (1)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Melanoma and Immunotherapeutics Service (6)
  4. GSK Faculty (5)
  5. Biostatistics Service (4)
  6. Epidemiology and Biostatistics (4)

More Groups

People
  1. Travis Hollmann (10)
  2. Jedd Wolchok (5)
  3. Yanyun Li (4)
  4. Claire Friedman (3)
  5. Taha Merghoub (3)
  6. Alexia Iasonos (2)

More People

Years
  1. 2025 (1)
  2. 2022 (2)
  3. 2020 (4)
  4. 2018 (1)
  5. 2017 (1)
  6. 2013 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Society for Immunotherapy of Cancer: Updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
    Review

    Taube, J. M.; Sunshine, J. C.; Angelo, M.; Akturk, G.; Eminizer, M.; Engle, L. L.; Ferreira, C. S.; Gnjatic, S.; Green, B.; Greenbaum, S.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Amadeus trial: Tumor agnostic pre- and ontreatment biomarkers of response to nivolumab plus ipilimumab correlate with ontreatment tumoral T cell infiltration
    Meeting Abstract

    Alayli, F.; Okrah, K.; Tsimberidou, A.; Drakaki, A.; Khalil, D.; Khan, S.; Hodi, S.; Oh, D.; Amouzgar, M.; Guatam, S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples
    Meeting Abstract

    Hether, T.; Howes, T.; Spencer, C.; Hollman, T.; Reeves, J.; Wells, D.; Friedman, C.; LaVallee, T.; Wolchok, J.; Warren, S.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
    Journal Article

    Friedman, C. F.; Snyder Charen, A.; Zhou, Q.; Carducci, M. A.; Buckley De Meritens, A.; Corr, B. R.; Fu, S.; Hollmann, T. J.; Iasonos, A.; Konner, J. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: A phase II trial
    Journal Article

    Zamarin, D.; Walderich, S.; Holland, A.; Zhou, Q.; Iasonos, A. E.; Torrisi, J. M.; Merghoub, T.; Chesebrough, L. F.; Mcdonnell, A. S.; Gallagher, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
    Guidelines

    Taube, J. M.; Akturk, G.; Angelo, M.; Engle, E. L.; Gnjatic, S.; Greenbaum, S.; Greenwald, N. F.; Hedvat, C. V.; Hollmann, T. J.; Juco, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
    Meeting Abstract

    Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save